Company Profile (AI Text)
Name: Kermode Biotechnologies 
Canonical URL: https://wefunder.com/kermode.biotech
Updated at: 2026-07-07T05:01:46Z

Tagline: AI-Powered Immunity: Protecting Farms from Viral Threats

Key claims:
- Total raised on Wefunder: 77211 | citation: https://wefunder.com/kermode.biotech#claim-total-raised
- Total investors: 22 | citation: https://wefunder.com/kermode.biotech#claim-total-investors

Verified facts:
- Total raised on Wefunder: 77211 | observed_at: 2026-07-07T05:01:46Z | expires_at: 2026-07-08T05:01:46Z
- Total investors: 22 | observed_at: 2026-07-07T05:01:46Z | expires_at: 2026-07-08T05:01:46Z

Computed metrics:
- total_amount_raised: 77211
- total_investors: 22
- team_size: 4
- featured_investor_count: 1
- faq_count: 2
- recent_post_count: 0

Quick facts:
- Viral outbreaks cost the swine industry $3B+ per year. | citation: https://wefunder.com/kermode.biotech#claim-fact-1
- Kermode's AI-driven technology arms the $180B global market with first-response immunotherapies. | citation: https://wefunder.com/kermode.biotech#claim-fact-2
- Backed by VC fund Summit Impact Partners. $1.5M raised from family offices. | citation: https://wefunder.com/kermode.biotech#claim-fact-3
- 5 vaccine candidates in pre-clinical trials, 2 ready for challenge. | citation: https://wefunder.com/kermode.biotech#claim-fact-4
- Team from Boehringer, Cornell, Danisco, GSK and NIH - with decades of expertise. | citation: https://wefunder.com/kermode.biotech#claim-fact-5
- 7 patents, 20+ filings, protection through 2043 in key markets. | citation: https://wefunder.com/kermode.biotech#claim-fact-6
- Revolutionary 'dominant negative' approach where others failed. | citation: https://wefunder.com/kermode.biotech#claim-fact-7
- A DIVA-compliant (traceable) vaccine that keeps America’s $23 billion pork trade certified and safe. | citation: https://wefunder.com/kermode.biotech#claim-fact-8

FAQ:
- Q: I love the partnerships, the team, and the ideal timing of just after the avian flu/egg pandemic. I do have a few questions though. 1) Why does ASFV has three separate treatments versus one for other viruses? 2) Can you clarify what level of testing you've done for your most a...
  A: Hi Jason, Thank you for your interest. I'm pleased to address your questions: 1. Efficacy Validation ASFV is a complex virus with over 150 genes and multiple immune evasion mechanisms, including T-cell inhibition, B-cell/antibody evasion, and macrophage toxicity. Our vaccine approach directly addresses these adaptations in relation to the viral replication cycle to prevent early infection establishment. Blocking these escape routes is critical to achieving high and lasting efficacy. 2. Regula...
- Q: 1. Efficacy validationCan you share the third-party or peer-reviewed data behind the “~100% efficacy” claim for your SVA/ASFV models? 2) What is your planned sequence with the USDA Center for Veterinary Biologics (or other regulators) for bringing these vaccines to market, and...
  A: Hi Sorin, Thank you for your thoughtful questions. 1) Our vaccines that are approaching ~100% protection include SVA and SIV, as we have seen in our unpublished and confidential early challenge models. However, we have multiple peer-reviewed publications building up to the early challenge studies that can be easily found on PubMed by searching 'Diego Diel SVA and SIV'. We have yet to test the ASFV vaccines in challenge studies and do not hold this claim at this time. 2) We are pursuing the US...